Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results